Silymarin for diabetic nephropathy: The challenges of botanical product research

American Journal of Kidney Diseases

Volumn 60, Issue 6, 2012, Pages 887-889

  Meyers, Catherine M ^a   Briggs, Josephine P ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; FLAVONOLIGNAN; INGENOL MEBUTATE; PLACEBO; SILYMARIN;

ANTIOXIDANT ACTIVITY; ANTIVIRAL THERAPY; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HEPATITIS C; HUMAN; IMMUNOMODULATION; LIVER DISEASE; OXIDATIVE STRESS; PRODUCT DEVELOPMENT; TREATMENT DURATION; UNITED STATES;

DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; MALE; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; SILYMARIN;

EID: 84868707556     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2012.09.002     Document Type: Editorial

References (15)

1. D.J. Newman, G.M. Cragg Natural products as sources of new drugs over the last 25 years J Nat Prod 70 2007 461 477
2. M. Lebwohl, N. Swanson, L.L. Anderson, A. Melgaard, Z. Xu, B. Berman Ingenol mebutate gel for actinic keratosis N Engl J Med 366 2012 1010 1019
3. H. Schilcher, S. Kammerer, T. Wegener Pflanzenprofile Leitfaden Phytotherapie 2007 Elsevier Urban & Fischer Munich, Germany 174
4. P.M. Derwick Medicinal Natural Products: A Biosythetic Approach 3rd ed. 2009 Wiley Chichester, United Kingdom
5. M.K. Fallahzadeh, B. Dormanesh, M.M. Sagheb Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic pateints with overt nephropathy: a randomized, double-blind, placebo-controlled trial Am J Kidney Dis 60 2012 896 903
6. K. Flora, M. Hahn, H. Rosen, K. Benner Milk thistle (Silybum marianum) for the therapy of liver disease Am J Gastroenterol 93 1998 139 143
7. P.M. Barnes, B. Bloom, R.L. Nahin Complementary and alternative medicine use among adults and children: United States, 2007 Natl Health Stat Rep 10 12 2008 1 23
8. S.J. Polyak, C. Morishima, V. Lohmann Identification of hepatoprotective flavonolignans from silymarin Proc Natl Acad Sci U S A 107 2010 5995 5999
9. A. Ahmed-Belkacem, N. Ahnou, L. Barbotte Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase Gastroenterology 138 2010 1112 1122
10. J. Wagoner, A. Negash, O.J. Kane Multiple effects of silymarin on the hepatitis C virus lifecycle Hepatology 51 2010 1912 1921
11. K.R. Reddy, S.H. Belle, M.W. Fried Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C Clin Trials 9 2012 102 112
12. M.W. Fried, V.J. Navarro, N. Afdhal Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial JAMA 308 2012 274 282
13. A. Rambaldi, B.P. Jacobs, C. Gluud Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases Cochrane Database Syst Rev 4 2007 CD003620
14. R.L. Hawke, S.J. Schrieber, T.A. Soule Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C J Clin Pharmacol 50 2010 434 449
15. D.C. Hopp, C.M. Meyers The challenges of dietary supplement research and considerations for future studies P. Coates, J.M. Betz, M.R. Blackman, Encyclopedia of Dietary Supplements 2nd ed. 2010 Marcel Dekker New York, NY